Novo Nordisk A/S (NYSE:NVO) Shares Bought by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 86.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 28,999 shares of the company's stock after purchasing an additional 13,437 shares during the period. Wilmington Savings Fund Society FSB's holdings in Novo Nordisk A/S were worth $3,453,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Sfmg LLC grew its holdings in shares of Novo Nordisk A/S by 15.0% in the third quarter. Sfmg LLC now owns 1,815 shares of the company's stock valued at $216,000 after purchasing an additional 237 shares in the last quarter. World Investment Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 36.9% in the 3rd quarter. World Investment Advisors LLC now owns 13,925 shares of the company's stock valued at $1,655,000 after buying an additional 3,750 shares during the period. Sanctuary Advisors LLC increased its stake in shares of Novo Nordisk A/S by 0.4% during the third quarter. Sanctuary Advisors LLC now owns 292,889 shares of the company's stock worth $34,874,000 after buying an additional 1,130 shares during the period. Anchor Investment Management LLC lifted its stake in Novo Nordisk A/S by 2.3% in the third quarter. Anchor Investment Management LLC now owns 13,447 shares of the company's stock worth $1,601,000 after acquiring an additional 297 shares during the last quarter. Finally, Tudor Financial Inc. acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $311,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $1.66 during mid-day trading on Friday, hitting $106.95. 6,250,388 shares of the stock were exchanged, compared to its average volume of 4,531,001. Novo Nordisk A/S has a 12-month low of $96.53 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $479.94 billion, a price-to-earnings ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40. The stock's fifty day simple moving average is $110.59 and its two-hundred day simple moving average is $126.27.

Analysts Set New Price Targets

Several research firms have recently issued reports on NVO. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $150.40.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.